Stuttgart
23.12.25 | 07:40
0,051 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,043 | 0,063 | 28.12. | |
| 0,049 | 0,054 | 23.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Hemostemix Inc (2): Hemostemix appoints Alper to scientific advisory board | 3 | Stockwatch | ||
| Di | Hemostemix Inc.: Hemostemix Appoints Dr. David B. Alper, to Lead Multidisciplinary Physician Education in the Use of ACP-01 | 290 | Newsfile | Calgary, Alberta--(Newsfile Corp. - December 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), an autologous stem cell company treating those who... ► Artikel lesen | |
| 19.12. | Hemostemix Inc (2): Hemostemix 4,713,090-unit private placement | 4 | Stockwatch | ||
| 12.12. | Hemostemix Inc (2): Hemostemix grants options to buy 963,000 shares | 2 | Stockwatch | ||
| 11.12. | Hemostemix Inc.: Hemostemix CEO Introduces Conformal Consciousness Hypothesis A = E/(hv) | 247 | Newsfile | Calgary, Alberta--(Newsfile Corp. - December 11, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) the leading autologous (patient's own) stem cell therapy company offering VesCell (ACP-01)... ► Artikel lesen | |
| 11.12. | Hemostemix Inc.: Hemostemix Grants Stock Options | 119 | Newsfile | Calgary, Alberta--(Newsfile Corp. - December 11, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that in accordance with its stock... ► Artikel lesen | |
| 11.12. | Hemostemix Inc (2): Hemostemix basket protocol pre-IND meeting set for Jan. | 3 | Stockwatch | ||
| 10.12. | Hemostemix Inc. Announces FDA Pre-IND Meeting and NBPP of $960,000 | 310 | Newsfile | Calgary, Alberta--(Newsfile Corp. - December 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy... ► Artikel lesen | |
| HEMOSTEMIX Aktie jetzt für 0€ handeln | |||||
| 05.12. | Hemostemix Inc (2): Hemostemix appoints Harding as patient care director | 3 | Stockwatch | ||
| 04.12. | Hemostemix Inc.: Hemostemix Welcomes Shaune Harding, OStJ, RN as Director of Patient Care & Clinical Operations | 278 | Newsfile | Calgary, Alberta--(Newsfile Corp. - December 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), a leader in autologous stem cell therapeutics for ischemic... ► Artikel lesen | |
| 03.12. | Hemostemix Inc.: Hemostemix Featured at Innovations in Wound Healing 2025, Key West, December 11-14 | 390 | Newsfile | Calgary, Alberta--(Newsfile Corp. - December 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce its participation as a premier... ► Artikel lesen | |
| 02.12. | Hemostemix Inc.: Hemostemix to Attend DFCon San Antonio and Closed its Private Placement | 309 | Newsfile | Calgary, Alberta--(Newsfile Corp. - December 2, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is proud to announce its participation in DFCon 2025, hosted by the American Limb Preservation... ► Artikel lesen | |
| 27.11. | Hemostemix Inc (2): Hemostemix to acquire two cardiology practices | 15 | Stockwatch | ||
| 26.11. | Hemostemix Inc.: Hemostemix Starts its Roll-up of Cardiology Practices, Acquiring its First Two | 387 | Newsfile | Calgary, Alberta--(Newsfile Corp. - November 26, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), is pleased to announce a binding Letter of Intent for the acquisition of the first two... ► Artikel lesen | |
| 21.11. | Hemostemix Inc (2): Hemostemix's ACP-01 dementia trial to be led by Shankle | 1 | Stockwatch | ||
| 20.11. | Hemostemix Inc.: Dr. William R. Shankle to Advance ACP-01 as a Treatment for Vascular Dementia | 198 | Newsfile | Calgary, Alberta--(Newsfile Corp. - November 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell (ACP-01)... ► Artikel lesen | |
| 18.11. | Hemostemix Inc.: Hemostemix Closes CDN$280,594 Private Placement | 411 | Newsfile | Calgary, Alberta--(Newsfile Corp. - November 18, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy... ► Artikel lesen | |
| 18.11. | Hemostemix Inc.: Hemostemix to Showcase Breakthrough Wound Healing Therapy at Innovations in Wound Care Conference Florida | 363 | Newsfile | Calgary, Alberta--(Newsfile Corp. - November 18, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), a leader in regenerative medicine, will attend the Innovations in Wound Care Conference... ► Artikel lesen | |
| 13.11. | Hemostemix Inc.: Hemostemix Presents ACP-01 Data at University of Florida Grand Rounds: Highlights Strong Safety, Functional Gains, and Florida Access Pathway | 573 | Newsfile | Calgary, Alberta--(Newsfile Corp. - November 13, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) today announced key highlights from its November 12, 2025 Grand Rounds presentation (to... ► Artikel lesen | |
| 05.11. | Hemostemix Inc (2): Hemostemix closes $461,230 first tranche of financing | 11 | Stockwatch |
1 2 3 4 5 Weiter >>
107 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,388 | +3,10 % | Revolutionäre Fortschritte: BioTech-Ideen für 2026! Bayer, Novo Nordisk, BioNxt, Vidac, BioNTech und Evotec! | Trotz eines schwierigen Umfelds 2025 bleibt der Biotech-Sektor fundamental attraktiv, da der medizinische Fortschritt nicht zum Stillstand kommt. Der rasante Einsatz von Künstlicher Intelligenz und... ► Artikel lesen | |
| QIAGEN | 38,985 | -0,35 % | QIAGEN N.V.: QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million | Return of approximately $500 million maximum approved by shareholders set to be completed on January 7, 2026 Capital return to be conducted through synthetic share repurchase combines a... ► Artikel lesen | |
| VALNEVA | 3,654 | -1,77 % | Wochenend-Analyse: Valneva-Aktie vor entscheidender Woche - Montag könnte alles ändern! | ||
| EPIGENOMICS | 0,890 | 0,00 % | PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Epigenomics... ► Artikel lesen | |
| NOVAVAX | 5,766 | -2,24 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| STRYKER | 301,70 | -0,59 % | Stryker Earnings Preview: What to Expect | ||
| CRISPR THERAPEUTICS | 47,000 | -3,69 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112) in Autoimmune Diseases and Hematologic Malignancies | -Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the... ► Artikel lesen | |
| CORE ONE LABS | - | - | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| OCUGEN | 1,259 | -0,12 % | Ocugen Provides Business Update with Third Quarter 2025 Financial Results | Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA)... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 28,970 | -1,63 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| PROTAGONIST THERAPEUTICS | 88,78 | -0,07 % | Protagonist Therapeutics: Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice | NEW YORK, NY / ACCESS Newswire / November 27, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") today announced that it has received a notification letter from the Nasdaq Listing Qualifications... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 39,640 | -1,59 % | Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday | ||
| VERA THERAPEUTICS | 53,58 | -3,75 % | Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy | Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46%... ► Artikel lesen | |
| CELCUITY | 102,25 | -0,35 % | Celcuity Inc.: Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer | MINNEAPOLIS, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the completion... ► Artikel lesen | |
| IMMUNOVANT | 26,160 | -2,68 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen |
Das Unternehmen HEMOSTEMIX INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,051 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HEMOSTEMIX INC finden Sie auf Wallstreet Online.